Courtin, Aurelie <br/><br/>
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.  [electronic resource] 

 -  British journal of cancer  Oct 2016 
 - 1069-1077 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2016.294  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Benzamides--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>Crizotinib<br/>Drug Resistance, Neoplasm--drug effects<br/>Erlotinib Hydrochloride--administration & dosage<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Humans<br/>Isoindoles--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mice, Inbred BALB C<br/>Mice, SCID<br/>Neoadjuvant Therapy--methods<br/>Neoplasm Recurrence, Local--prevention & control<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrazoles--administration & dosage<br/>Pyridines--administration & dosage<br/>Xenograft Model Antitumor Assays